Lithium toxicity

Background

  • Lithium remains the most effective treatment for bipolar disorder despite availability of newer agents
  • Mechanism of action poorly understood; modulates neurotransmitter signaling
  • Narrow therapeutic index (therapeutic level: 0.6-1.2 mEq/L)
  • Pharmacokinetics:
    • Rapidly absorbed (peak 1-2h for immediate release; 4-12h for sustained release)
    • Initially distributes in extracellular fluid → gradually redistributes to CNS (up to 24 hours)
    • 95% renally excreted; handled like sodium by proximal tubule
  • Lithium toxicity rarely fatal (only 11 deaths out of 6815 reported toxic exposures in 2012)[1]

Common Precipitants

Clinical Features

Three recognized patterns of toxicity[2]:

Acute Ingestion

  • Patient not previously on lithium (no body stores)
  • GI symptoms predominate: nausea, vomiting, diarrhea, abdominal pain (earliest/most common)
  • Cardiac: bradycardia, QT prolongation, T-wave flattening/inversion, Brugada-like pattern[3]
  • CNS depression is a late finding (takes time for lithium to redistribute to brain)
  • Serum levels may be very high but do not correlate with clinical toxicity

Acute-on-Chronic

  • Patient on chronic lithium who takes supra-therapeutic dose
  • Mixed GI and CNS symptoms

Chronic Toxicity

  • Insidious onset in patients on chronic therapy
  • Due to increased absorption or decreased elimination
  • CNS symptoms predominate (generally more severe than acute):
    • Mild: fine tremor, drowsiness, muscle weakness
    • Moderate: hyperreflexia, confusion, coarse tremor, ataxia, slurred speech
    • Severe: seizures, myoclonus, coma, extrapyramidal symptoms
  • Hypothyroidism (lithium inhibits thyroid hormone release)

SILENT Syndrome[4]

  • Syndrome of Irreversible Lithium-Effectuated Neurotoxicity
  • Neurologic dysfunction persisting >2 months after cessation of lithium
  • Cerebellar dysfunction (dysarthria, ataxia, gait instability), peripheral neuropathy, dementia

Differential Diagnosis

Template:Heavy metals DDX

Evaluation

  • Lithium level:
    • Therapeutic: 0.6-1.2 mEq/L
    • Levels >1.5 mEq/L may be associated with toxicity (chronic > acute for same level)
    • Do NOT use green top (lithium heparin) tube — falsely elevates level
    • Serum levels do not predict CNS levels and only roughly correlate with clinical symptoms
    • Serial levels every 2-4 hours (especially after overdose or post-HD)
  • BMP: creatinine, sodium (often hyponatremic or hypernatremic), calcium
  • TSH (chronic use → hypothyroidism)
  • ECG: QT prolongation, T-wave changes, bradycardia, Brugada pattern
  • Acetaminophen and salicylate levels (possible coingestants)
  • Urinalysis (urine specific gravity to evaluate concentrating ability)

Management

GI Decontamination

  • Whole bowel irrigation (WBI): only for sustained-release tablet ingestion
    • PEG solution via NG at 1-2 L/hr (adults)
  • Activated charcoal is NOT effective (lithium is not adsorbed)
  • Gastric lavage generally not effective and potentially harmful

Fluid Resuscitation

  • Most important initial intervention — most patients have volume/sodium deficit
  • NS is preferred (restores sodium, promotes renal lithium excretion)
  • Give 2L NS bolus, then 200 mL/hr (or 2× maintenance)
  • Target UOP 1-2 mL/kg/hr
  • Avoid forced diuresis with loop diuretics (may worsen lithium toxicity)

Hemodialysis

  • Most effective method of lithium removal
  • Must follow serial lithium levels post-HD — levels will rebound due to tissue redistribution
  • May require multiple sessions
  • EXTRIP Workgroup Indications[5]:
    • Recommended (1D): impaired kidney function AND Li >4.0 mEq/L
    • Recommended (1D): clinical deterioration (decreased LOC, seizures, life-threatening dysrhythmias) regardless of level
    • Suggested (2D): Li >5.0 mEq/L
    • Suggested (2D): expected time to Li <1.0 mEq/L with optimal management >36 hours
  • Contraindication to aggressive fluids (CHF) lowers threshold for HD
  • Consult toxicology and nephrology — complex decision

Endpoint of Dialysis

  • Continue HD until lithium level <1.0 mEq/L
  • Recheck level 6-8 hours post-HD for rebound

Disposition

  • Discharge considerations (acute ingestion):
    • Asymptomatic after 4-6 hours observation
    • Two downtrending lithium levels
    • No worsening renal function
  • Admit:
    • All patients with Li level >1.5 mEq/L
    • All sustained-release preparation ingestions (regardless of Li level)
    • Any patient with neurologic symptoms
    • Any patient requiring hemodialysis
  • Poison control: 1-800-222-1222

See Also

References

  1. Mowry JB, et al. 2012 annual report of the AAPCC NPDS. Clin Toxicol (Phila). 2013;51:949-1229. PMID 24359283
  2. Waring WS, et al. Pattern of lithium exposure predicts poisoning severity. QJM. 2007;100(5):271-6. PMID 17410291
  3. Canan F, et al. Lithium intoxication related multiple temporary ECG changes. Cases Journal. 2008;1:156. PMID 18801176
  4. Adityanjee, et al. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol. 2005;28(1):38-49. PMID 15681811
  5. Decker BS, et al. Extracorporeal treatment for lithium poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol. 2015;10(5):875-887. PMID 25583293
  • Baird-Gunning J, et al. Lithium poisoning. J Intensive Care Med. 2017;32(4):249-263. PMID 27055773
  • Ott M, et al. Lithium intoxication: incidence, clinical course and renal function — a population-based retrospective cohort study. J Psychopharmacol. 2016;30(10):1008-1019. PMID 27530173